This study looks at how well Dostarlimab works compared to a placebo in adults with head and neck squamous cell carcinoma. The goal is to find out if Dostarlimab is safe and effective when given after chemoradiation treatment. Participants will have recently diagnosed cancer that cannot be removed by surgery and have completed treatment with cisplatin and radiation.
This is a Phase 3 trial, which means it is looking at how well the treatment works and how safe it is. The trial is FDA-regulated and aims to include about 864 participants.
Who can join
Adults aged 18 and older can join the study. It is open to both men and women. To be eligible, participants must have specific types of head and neck cancer and meet other health criteria. The trial team will check who can join.
Condition
Neoplasms, Head and Neck
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will be randomly placed into two groups. One group will receive Dostarlimab through an IV infusion, while the other group will receive a placebo. Everyone will be monitored for how well the treatment works and any side effects.
Where
This trial is enrolling at 36 locations. Recruiting sites are listed first.
A surgeon who treats mouth cancer and voice box cancer at Rajiv Gandhi Cancer Institute & Research Centre. Treats mouth cancer, voice box cancer, throat cancer and thyroid cancer.
Professor and Chair of the Department of Radiation Oncology at the University of Alabama. Treats mouth cancer and voice box cancer. Recognized at state, national or international level.
A surgeon who treats mouth cancer and voice box cancer at Rajiv Gandhi Cancer Institute & Research Centre. Treats mouth cancer, voice box cancer and throat cancer.